Teva Pharmaceutical Industries, a generic pharmaceutical company, has announced positive results from a study in which Azilect demonstrated selective Mao-B inhibition at the approved dose of 1mg. Based on these positive results, Teva has said it will work with the FDA to modify the Azilect label to reflect this data.


Selectivity was tested by evaluating the interaction between tyramine and rasagiline in healthy subjects. This double blind placebo controlled study was conducted in order to comply with the FDA's requirement for full characterization of rasagiline's selectivity. In the study, rasagiline was compared to phenelzine, a known non-selective inhibitor.

Non selective Mao inhibitors may have some contra indications with certain foods and drugs. These limitations are not associated with selective Mao inhibitors and therefore they can be broadly prescribed.